Glenmark launches generic glaucoma treatment ophthalmic solution

2 hours ago 1

Glenmark Pharmaceuticals Inc, USA connected Wednesday said it has launched Travoprost ophthalmic solution utilized successful the attraction of glaucoma.

The Travoprost ophthalmic solution ( 0.004 per cent ionic buffered solution) is bioequivalent and therapeutically equivalent to the notation listed drug, Travatan Z ophthalmic solution USP, 0.004 per cent of Sandoz, Inc, the institution said successful a statement.

Glenmark Pharmaceuticals Inc Senior Vice President, Sales & Marketing Jim Brown said the motorboat of Travoprost ophthalmic solution USP, 0.004 per cent adds to the company's portfolio of medicine ophthalmic products.

"This summation highlights our committedness to gathering marketplace needs and providing high-quality solutions for our customers," helium added.

Citing IQVIA income information for the 12-month play ending September 2024, the institution said Travatan Z ophthalmic solution 0.004 per cent had achieved yearly income of astir $66.2 million.

*** Disclaimer: This Article is auto-aggregated by a Rss Api Program and has not been created or edited by Nandigram Times

(Note: This is an unedited and auto-generated story from Syndicated News Rss Api. News.nandigramtimes.com Staff may not have modified or edited the content body.

Please visit the Source Website that deserves the credit and responsibility for creating this content.)

Watch Live | Source Article